BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Still no scare for Ohtuvayre: Roche IL-33 COPD data mixed
The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing...

More in BioWorld

BioWorld MedTech

FDA expands Boston Sci’s Watchman label to post-ablation
The U.S. FDA expanded the approval for use of Boston Scientific Corp.’s Watchman Flx and Watchman Flx Pro left atrial appendage closure (LAAC) devices to include...

More in BioWorld MedTech

BioWorld Science

Coinfections and diversity paint the many shades of HIV cure
We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses and...

More in BioWorld Science

BioWorld Asia

Hengrui/Kailera obesity asset delivers solid weight loss in phase III
A glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist developed by Jiangsu Hengrui Pharmaceuticals Co. Ltd. and licensed by...

More in BioWorld Asia

BioWorld Insider Podcast

Robert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.